Market Overview

Cell Therapeutics Presents Interim Results from Phase 2 Tosedostat Trial in Older Patients with AML or MDS at ASH


Cell Therapeutics (NASDAQ: CTIC) today announced promising interim results from an investigator-initiated Phase 2 clinical trial of tosedostat in combination with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival. Tosedostat is administered orally and has been previously shown to induce complete remissions as monotherapy in relapsed or refractory AML. Researchers presented the findings from this combination study today for the first time at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition held December 7–10 in New Orleans, La.#ASH13

See full press release

Posted-In: News Guidance Financing Management Global


Related Articles (CTIC)

View Comments and Join the Discussion!

Savient Pharmaceuticals Announces Agreement on Use of Cash Collateral

InterDigital's Innovation Signs Collaboration Agreement with VTT Technical Research Centre of Finland